Postinjection delirium/sedation syndrome

Adverse reactions data from trials of the long-acting injection of olanzapine have been reviewed, looking for cases of postinjection delirium/sedation syndrome (PDSS) [114 ]. Based on about 45000... 

Drug administration route Postinjection delirium/sedation syndrome is a serious adverse event that has been associated with olanzapine pamoate [78 ]. 

Four SGA long-acting injections are currently available risperidone microspheres, olanzapine pamoate, paliperidone palmitate and aripiprazole extended-release injection. The extended-release characteristics are achieved differently with each drug. A case analysis of clinical frials with olanzapine pamoate (2000-2008) reported an occurrence of postinjection delirium/sedation syndrome in approximately 0.07% of injections or 1.4% of patients [78 ]. A review of the published literature and clinical trial databases for olanzapine pamoate, risperidone microspheres and paliperidone palmitate found only one other case of postinjection delirium/sedation syndrome occurring in a patienf on placebo in a paliperidone palmitate trial. In four randomised, double-blind, placebo-controlled trials of paliperidone palmitate, the most common treatment-emergent adverse event was somnolence/sedation overall treatment discontinuation rates due to adverse events were similar to placebo. 

---